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Multiphase microfluidics has attracted significant interest in making micro- and
nanostructures for various applications because of its capabilities in precisely controlling and
manipulating a small volume of liquids. In this review, we introduce the recent advances in
making micro- and nanostructures for pharmaceutical applications, including microparticles
and microcapsules for controlled release, nanoparticles for drug delivery and microgels for
3D cell culture. With the development of more advanced microfluidic systems, the research
focus in this field has shifted from making simple micro- and nanostructures to
multifunctional systems to achieve more desirable functions. However, these multifunctions
may lose their advantages that have been demonstrated in vitro once they are applied in vivo
or later in human. The key challenge is a lack of fundamental understanding of the
interactions between the micro- and nanomaterials and the biology systems. Consequently,
the translation of these advanced materials lags far behind their extensive laboratory research.
To better understand the micro- or nano-bio interactions, the development of new in vivo-
mimicking models is imperative. Microfluidics has demonstrated its great potential in
creating physiologically relevant models including 3D cell culture, tumor-on-a-chip and
organs-on-a-chip. Therefore, efforts towards developing 3D cell culture and biomimetic chips
including tumor-on-a-chip and organs-on-chips for faster and reliable evaluation of these
micro- and nanosystems are also highlighted.




There has been a long-standing need for improved pharmaceutical formulations that are
capable of delivering therapeutics (drugs, genes, and biomolecules) at a controllable rate to
specific sites (cell, tissue or organ). Novel carriers hold great promise in achieving enhanced
bioavailability, reduced cytotoxicity, targeted delivery, controlled release, and improved
efficacy that can ultimately result in desired therapeutic responses in the body. Among these
carriers, micro- (Kurmi et al., 2010; Leong and Wang, 2015; Skorb and Möhwald, 2014) and
nano- (Gref et al., 2012; Peer et al., 2007; Schroeder et al., 2010; Wang et al., 2012)
structures have attracted significant research interest because of their tunability in physical
(size, structures, porosity, and mechanical strength) and chemical (compositions, reactivity,
biocompatibility, and biodegradability) properties, and flexibility in integrating different
functions, such as for active/passive targeting, stimuli-responsive release, and
diagnostics/imaging. To enable their full potential in practical pharmaceutical applications,
the development of advanced and robust platform technologies for the manufacture of micro-
and nanostructured materials with high degree of uniformity (size, size distribution, and
shape), batch-to-batch reproducibility and scale-up possibilities, becomes highly essential.
Microfluidics as modern technology has been transforming some of the industrial
practices for controllable synthesis of multicomponent carrier systems with sophisticated
structures and multiple functions (Riahi et al., 2015; Vladisavljevic et al., 2013). Multiphase
microfluidics involves two or more partially or immiscible fluids in contact. It has been
commonly applied to enhance mixing, increase mass transfer across phase boundaries, and
reduce dispersion (Günther and Jensen, 2007; Zhao and Middelberg, 2011). Also,
microfluidics has unique characteristics such as pico- to nanoliters of reagents, nano- to
microseconds of mixing, reaction and self-assembly, real-time monitoring/imaging and direct
scale-out. These properties offer significant advantages for relatively low-cost and high-
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throughput production of micro- (microparticles, microcapsules, and microgels) (Gañán-
Calvo et al., 2013; Shim et al., 2013; Zhao, 2013) and nanocarriers (polymeric nanoparticles,
liposomes, and hybrid nanoparticles) (Khan et al., 2013; Khan et al., 2015b; Zhao et al.,
2011).
Despite the vast amount of efforts in developing various micro-/nano-carriers, their
translation from in vitro to animal studies (preclinical) and finally human trials (clinical) has
been tremendously expensive with long timelines and quite often fails at the later stage of
their development even after entering human clinical trials. Until now, only a few
nanosystems have been approved by the U.S. Food and Drug Administration (FDA) for
human use, for example, Doxil (a liposomal formulation encapsulating Doxorubicin)
(Koynova and Tenchov, 2015) and Abraxane (based on the nanoparticle albumin-bound (nab)
technology to deliver Paclitaxel) (Qiang et al., 2009) for cancer treatments. One of the
hurdles is the lack of robust in vitro or in vivo systems that can predict the behavior of drugs
and carriers in the human body. In vivo animal models have been widely used but cannot
accurately predict human responses due to inter-species differences. Also, animal
experiments are time-consuming, high cost, and have ethical concerns. Microfluidics offers
structures and networks at the micrometer length scale comparable to relevant physiological
length scales and can incorporate fluid flows and mechanical forces capable of mimicking the
in vivo microenvironment. Therefore, it enables the investigation of complex interactions
between these micro-/nanosystems and biological systems. Furthermore, integration of tumor
spheroids or organoids with microfluidics to build tumor-on-a-chip, organs-on-a-chip, and
ultimately human body-on-a-chip creates a platform that cannot be achieved by conventional
cell and tissue culture in well plates. Thus, organs-on-a-chip can be useful for predicting
preclinical and even clinical performances of new therapeutics and micro-/nano-delivery
vehicles at early stages of drug development.
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In this review, we will critically review the recent advances in making micro-
(microparticles, microcapsules, and microgels) and nanostructures (polymeric, liposomes,
and hybrid nanoparticles) in microfluidics for therapeutic delivery and controlled release,
with a focus on new structures, new functions, and their pharmaceutical applications. We will
also highlight recent development in making microgels for 3D cell culture as well as tumor-
on-a-chip and organs-on-a-chip, which provide rapid and reliable screening and evaluation
tools for accelerating the development of drug delivery systems.
2. Well-controlled synthesis of micro- and nanostructures and their pharmaceutical
applications
A wide variety of micro- and nanostructures have been synthesized using microfluidics (Fig.
1), including microparticles, microcapsules, microgels, and nanoparticles made of various
materials including synthetic polymers, natural polymers, lipids, and hybrid materials. This
section will introduce the synthesis of these micro- and nanostructures and their
pharmaceutical applications.
Fig. 1 Types of micro- and nanostructures synthesized using microfluidics
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2.1 Synthesis of microstructures and their applications
2.1.1 Microparticles
Microparticles herein are defined as particles with a size ranging from 1 to 1000 µm.
Microfluidics offers several unique advantages for preparing microparticles, such as precise
control over particle size, surface morphology, and high flexibility in making microparticles
with various materials and different structures. Microfluidic approaches have been widely
explored for making a wide variety of microparticles in the past decade. Initially, researchers
have been focusing on making microparticles made of different materials for encapsulation of
one drug or more for slow release applications, as well as precise control over their size and
surface texture (Fig. 2). Then the studies moved on to make microparticles with more
complex structures, for example, core–shell microparticles, Janus particles, and even more
complex shapes, coupled with triggered release by pH, temperature, light, etc. Recently, the
research focus has been shifting from the development of different microfluidic devices and
methods for making various microparticles for encapsulation and controlled release
(Bokharaei et al., 2016) to the fabrication of microparticles made of new materials, more
complex structures, and multiple functions for more sophisticated applications, such as
multistage pH-responsive properties, precise control over drug loading into each domain,
versatile loading of different drugs and tailored release kinetics. Several articles reviewed the
synthesis of polymeric microparticles (Wang et al., 2014a), non-spherical polymeric
microparticles (Baah et al., 2012), microparticles based on emulsion templates (Wong et al.,
2006; Zhao, 2013), porous microspheres (Duncanson et al., 2012b; Fan et al., 2013), designer
microparticles for encapsulation and controlled release applications (Duncanson et al., 2012a;
Kong et al., 2012). In this review, we highlight the new development of this field since 2013.
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Fig. 2 Development of microparticles for various applications.
Microparticles with complex shapes
Microparticles are generally fabricated by a strategy called droplet-to-particles through
different solidification methods, including UV polymerization (Khan et al., 2015a; Liu et al.,
2016a; Xue et al., 2015), solvent evaporation (Min et al., 2016), spray drying (Liu et al.,
2015a; Liu et al., 2016c; Liu et al., 2012) and ionic cross-linking (Chan et al., 2009; Liu et al.,
2016b). In addition to these conventional approaches, which have been widely used to
fabricate spherical particles, a number of other ways to make non-spherical polymer
microparticles have been developed. Microparticles with complex 3D shapes can be made
through the simple tuning of mold swelling and capillarity using 2D micromolds (Choi et al.,
2015b). A sequential micromolding method was developed to make multicompartmental
polymeric microparticles. Basically, primary and secondary compartments were formed in
micromolds sequentially based on surface-tension induced droplet formation followed by
simple  photopolymerization  (Choi  et  al.,  2015a).  Additionally,  3D-printing  (Chen  et  al.,




Janus particles and multicompartmental particles
Instead of relying on the physical confinement to generate complex microparticles, a
number of new strategies have also been developed. Drug-loaded Janus particles can be
prepared using side-by-side microcapillary devices (Khan et al., 2014). Min et al. made
multiple compartment microparticles through phase separation (Min et al., 2016). Uniform
solvent droplets containing two immiscible polymers (one is biodegradable, and the other is
pH-responsive) were generated in a capillary microfluidic device. With the evaporation of the
solvent the two polymers underwent phase separation followed by co-solidification, leading
to the formation of microparticles with distinct compartments. When two drugs with different
hydrophobicity were initially dissolved in the solvent along with the two polymers, they were
able to concentrate in the compartment that they had high affinity. Because of the properties
of the two polymers, they can provide unique release profiles of the model drugs. Hayakawa
et al. also reported the generation of multicompartmental microparticles with complex shapes
(Hayakawa et al., 2016). Their method was based on the Marangoni and diffusional flows of
droplets containing two or more compositions through double-, triple- or even septuple-glass
capillary-based centrifugal microfluidic device. Ekanem et al. produced biodegradable
poly(ᴅʟ-lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) microparticles with
different shapes, internal structures and surface morphologies (Ekanem et al., 2015). Janus
and hemispherical particles were generated by solvent-induced phase separation, and less-
porous particles and porous golf-ball-like particles were made by adding non-clay or porogen
in the dispersed phase. Dong et al. made hybrid organic–inorganic (PLGA–TiO2)
microparticles with tunable surface textures by changing the mass ratio between titanium
tetraisopropoxide  (TTIP)  and  PLGA in  the  droplet  phase.  The  hydrolysis  of  TTIP formed a
thin layer of TiO2 and then a wrinkled surface formed as a result  of the removal of organic




Microparticles with core–shell structures can provide controlled release profiles, such
as more sustained release, stimuli-responsive release. Monodisperse PLGA–alginate core–
shell microspheres were fabricated using double emulsions as the templates in a
microcapillary device (Wu et al., 2013). The alginate-shell was used to modulate the release
profile. Uniform gelatin–alginate core–shell microparticles were designed as a pH-responsive
drug carrier. They were synthesized using sodium alginate solution containing gelatin
capsules as the dispersed phase (Huang et al., 2014). The alginate-shell was then solidified
through cross-linking in a CaCl2 solution. As the alginate-shell is stable in acid environments,
the core–shell microparticles remained intact in gastric solution for more than 3 h. In contrast,
the alginate-shell could swell under alkali conditions and then release the drug. This core–
shell microparticles are potential for oral drug delivery to the intestine. Thermo-responsive
core–shell microparticles were prepared using poly(N-isopropylacrylamide) (PNIPAM) as the
core and porous ethyl cellulose shell embedded with PNIPAM gates (Yu et al., 2012). In
addition to triggers like pH, temperature, light, etc., external fields can also be used as a
trigger. For example, perfluorocarbon–alginate core–shell microparticles remained intact up
to 21 days but were disrupted easily after exposure to ultrasound for 15 mins (Duarte et al.,
2014).
Multifunctional microparticles
Multifunctional microparticles have also attracted significant interests in the past
several years. Multidrug-loaded microparticles demonstrated a sustained release of both
drugs (Leon et al., 2015). Quantum dots (QD)-encoded poly(ethylene glycol) diacrylate
(PEGDA) microbeads with the size ranging from 7 to 120 µm were synthesized for
suspension assay (Liu et al., 2016a). Magnetic-fluorescent Janus alginate microparticles were
made to achieve the luminescent labeling and magnetic separation. The particles were made
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using two alginate streams with one doped with Fe3O4 nanoparticles and the other one with
CdSe/ZnS quantum dots as the dispersed phase (Chan et al., 2009). Kim et al. developed
multifunctional alginate microspheres for magnetic resonance imaging (MRI) and a sustained
drug-release profile by encapsulating magnetic clusters of ultrasmall superparamagnetic iron
oxide (USPIO) nanoparticles and a drug (amonafide) (Kim et al., 2015a). Zhang et al.
developed multfunctional nano-in-micro particles for orally administered targeted drug
delivery (Zhang et al., 2014). Porous silicon nanoparticles (PSi) loaded with a drug was
modified using a mucoadhesive polymer, poly(methyl vinyl ether-co-maleic acid)
(PMVEMA) through a poly(ethyleneimine) (PEI) as a linker. The modified PSi-PEI-
PMVEMA nanoparticles were then encapsulated inside a pH-responsive hydroxypropyl-
methylcellulose acetate succinate based polymer (ASHF). The nano-in-micro systems were
further engineered for multistage pH-responsive controlled multidrug delivery. A drug
atorvastatin was firstly loaded into the PSi which were further encapsulated into a pH
responsive polymer microparticles containing another drug celecoxib. Therefore, this nano-
in-micro drug delivery system remained stable in acidic somatic conditions thus prevent any
premature release in the gastrointestinal (GI) tract, while the alkaline pH condition in the
upper intestinal region triggered the drug release. Instead of using a multistep process by first
forming nanoparticles ex situ followed by producing nano-in-micro particles in microfluidic
devices, a semi-continuous process was developed for making nano-in-micro Trojan particles
combining an elongational-flow micromixer for producing polymerizable nanoemulsions
coupled with a co-axial microcapillary for forming microparticles (Khan et al., 2015a).
2.1.2 Microcapsules
Microcapsules refer to core–shell microstructures composed of a solid shell that
surrounds a core-forming space available to entrap active molecules. The core–shell structure
of microcapsules offers several advantages over their solid and porous counterparts. The core
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allows the encapsulation of various cargoes, ranging from drugs (Li et al., 2015; Liu et al.,
2014; Vasiliauskas et al., 2015; Yang et al., 2009; Yang et al., 2014), proteins (Pessi et al.,
2014; Yeh et al., 2011; Zhang et al., 2013), vitamins (Liu et al., 2013; Yeh et al., 2013), cells
(Ferreira et al., 2013; Kim and Kang, 2014; Mendes et al., 2012) to imaging agents
(Abbaspourrad et al., 2013a; Abbaspourrad et al., 2013b; Gokmen et al., 2009) and magnetic
nanoparticles (Ge et al., 2014; Liao and Su, 2010; Yang et al., 2009). Also, microcapsules
with gas filled in the core have attracted interests (Abbaspourrad et al., 2013c; Yoon et al.,
2015) especially for acoustic imaging as they are more echogenic than liquid-filled
microcapsules. The shells of microcapsules, on the other hand, function as protective barriers
for the encapsulated cargo, and its compositions and synthesis conditions determine the
physical (e.g., mechanical strength, shell thickness, and diffusivity) and chemical (e.g.,
biocompatibility, biodegradability, and functionality) properties of the resultant
microcapsules. Droplet-based microfluidics has been widely used to fabricate microcapsules.
Typically, single or double emulsions are used as templates which are then solidified to form
microcapsules through a number of solidification methods including: evaporation-induced
solidification (Abbaspourrad et al., 2013a; Abbaspourrad et al., 2013b), extraction-induced
solidification (Foster et al., 2010; Liao and Su, 2010; Vasiliauskas et al., 2015), UV
polymerization (Abbaspourrad et al., 2013c; Liu et al., 2014; Zhang et al., 2013; Zieringer et
al., 2015), and layer-by-layer deposition (Gokmen et al., 2009).
Microcapsules capable of releasing encapsulated cargoes in a controlled and predictable
manner are essential for pharmaceutical applications. Therefore, stimuli-responsive materials
are often incorporated into the core or the shell. The release of cargo can be triggered by
external stimuli, such as, acids/bases (Abbaspourrad et al., 2013b; Liu et al., 2013;
Vasiliauskas et al., 2015; Yang et al., 2014), organic solvents (Abbaspourrad et al., 2013a),
biomolecules (Zhang et al., 2013), and magnetic fields (Ge et al., 2014; Liao and Su, 2010;
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Yang et al., 2009). For example, Zhang et al. developed thermo- and glucose-responsive
microcapsules based on double emulsion templated methods (Zhang et al., 2013). The insulin
encapsulated microcapsules exhibited reversible and repeated swelling/shrinking response to
glucose concentration at 37ºC hence triggering insulin release. Although microcapsules with
triggered-release properties have been developed, cargo leakage still presents a technological
challenge which may compromise their applications. To minimize unwanted cargo loss,
Zieringer et al. utilized perfluoropolyether as the shell material, which has been demonstrated
to retain 98% of the encapsulated small molecules (i.e., CaCl2) over four weeks and the salts
can be released using osmotic stress-induced bursting mechanism (Zieringer et al., 2015).
Moreover, the porosity and functionality of microcapsules can be engineered by
incorporating silica particles on the shell during the synthesis of microcapsules, and the
porosity can then be formed after removal of the silica particles using alkaline solutions. To
enhance the utilities of microcapsules in pharmaceutical applications, site-specific targeted
delivery of microcapsules with direction-specific controlled release of cargo can be used (Ge
et al., 2014; Yang et al., 2009). For example, Yang et al. synthesized smart microcapsules of
poly(caprolactone) for combined magnetic targeting, fluorescent imaging, and controlled
drug release properties by encapsulating Fe3O4 nanoparticles, CdTe quantum dots, and
anticancer drug tamoxifen, respectively (Yang et al., 2009).
2.1.3 Microgels
Microgels are micrometer-sized gel particles consisting of three-dimensional (3D)
polymer networks. Various types of natural and synthetic polymers have been used for
making microgels, e.g., alginate (Utech et al., 2015), agarose (Shi et al., 2013),
chitosan/dextran (Oh et al., 2014), gel-forming peptides (Tsuda et al., 2010), poly(N-
isopropyl acrylamide) (PNIPAM) (Seiffert and Weitz, 2010), and poly(2-
methacryloyloxyethyl phosphorylcholine) (Park et al., 2014). The polymer-chain chemistry
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of microgels determines their hydrophilicity/hydrophobicity which, in turn, determines the
types of solutions where the microgels can be dispersed (e.g., in aqueous or organic solvents)
as well as the types of cargoes that can be loaded. Due to their open network structure,
microgels can sequester functional cargoes to their interstitial spaces by equilibrium
partitioning between the solution and microgels phases (Chen et al., 2010). Electrostatic
interaction  (Chen  et  al.,  2010;  Kim  et  al.,  2007),  hydrophobic  interaction  (Chen  et  al.,
2010), hydrogen bonding (Fang et al., 2010), or covalent conjugation (Utech et al., 2015)
may play an important role for the adsorption of cargoes into the microgels’ polymer-
network. The cargoes can be released from the microgels either by passive- or active-
diffusion  driven  by  swelling/shrinking  of  the  microgels  due  to  external  stimuli  such  as
temperature (Jagadeesan et al., 2011), pH (Lu et al., 2015), and light (Luo et al., 2014). The
abilities of microgels to encapsulate and release drugs have enabled them for controlled drug
delivery (Hu et al., 2012; Lu et al., 2015). Other functional cargoes, e.g., thermo-responsive
nanoparticles (Luo et al., 2014), dyes (Park et al., 2014; Xu et al., 2015), quantum dots and
magnetic nanoparticles (Kim et al., 2007), have been encapsulated in microgels,
demonstrating their versatile utilities for pharmaceutical applications. Furthermore, microgels
have been used for cell encapsulation and 3D cell culture which will be discussed in detail in
Section 3.1.
Microgels are commonly fabricated using droplet-based microfluidics. Droplets
containing a pre-microgel mixture are formed in an immiscible carrier phase, and then turn in
microgel particles through various subsequent droplet gelation methods, such as chemically
(e.g., by photo-polymerization (Jagadeesan et al., 2011; Lu et al., 2015; Park et al., 2014) and
free-radical copolymerization (Seiffert, 2012)) or physically (e.g., by temperature changes
(Shi et al., 2013) and ionic cross-linking (Guo et al., 2011; Miyama et al., 2013)). The size of
microgels depends on the size of the emulsified droplets, thus is tunable by adjusting the flow
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rates of the fluids during the microfluidic droplet formation or by controlling the dimensions
of the microfluidic devices. In addition to particle size, well-defined mesh size and its
homogeneity within microgels play important roles in the precision regulation of the release
kinetics in pharmaceutical applications. The mesh size of microgels is characterized by the
molecular weight between cross-links (Park et al., 2014). Moreover, the shape of the droplets
generated by microfluidic devices is generally spherical because of the interfacial tension
between the continuous and dispersed phases. By controlling interfacial tension and
viscoelastic properties of the droplets, microfluidic droplet templating can also serve to form
microgels with complex morphology, including yarn-ball (Miyama et al., 2013), pear-like,
mushroom-like, red blood cell-like (Hu et al., 2012), ellipse, triangle, and dumb-bell (Seiffert,
2012). These non-spherical microgels revealed unique properties such as anisotropic
responses to an external force, large surface area.
2.2 Synthesis of nanostructures and their applications
2.2.1 Synthetic polymer nanoparticles
Over the years, a variety of synthetic polymers has been explored for the preparation of
nanoparticles (NPs) as drug delivery nanocarriers using microfluidic approaches. Poly(lactic-
co-glycolic acid) (PLGA) (Hines and Kaplan, 2013; Makadia and Siegel, 2011), poly(lactic
acid) (Kolishetti et al., 2010), poly(methyl methacrylate) (PMMA) (Anton et al., 2012) and
Pluronic F-127 (Capretto et al., 2011) have gained paramount attention owing to their
biocompatibility and biodegradability. PLGA is one of the most popular and extensively
researched synthetic polymer for pharmaceutical applications and is considered as the “gold
standard” for controlled release studies. PLGA-based NPs have a broad range of applications
because of their unique properties such as versatile degradation kinetics, non-toxicity,
biocompatibility, and the U.S. Food and Drug Administration (FDA) approval for human use.
Compared to traditional beaker methods, microfluidic technology offers a reproducible and
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controllable platform for rapid NP synthesis with wide-ranging properties (Karnik et al.,
2008; Zhao et al., 2011). The ability of microfluidic systems to rapidly mix reagents
providing homogeneous reaction environments and to vary the reaction conditions
continuously allowing reagent addition during the progress of a reaction are the key features
that make them attractive for the NP synthesis.
Two kinds of microfluidic methods have been developed for the synthesis of PLGA
NPs i.e. droplets and flow focusing. Hung et al. employed a droplet-based approach to
precipitate the PLGA NPs. Water and PLGA solution (in an organic solvent, dimethyl
sulfoxide (DMSO)) were sheared by mineral oil into monodispersed droplets, then fused in a
widening chamber to initiate the mixing hence PLGA NPs precipitation due to the solubility
difference (PLGA solubility in water is lower than in DMSO) (Hung et al., 2010). PLGA NPs
of up to three orders of magnitude difference in size (70 to 482 nm) can be synthesized by
changing the flow rate ratio of water to the PLGA–DMSO (1:1 to 1:4).
Flow-focusing microfluidics is another widely-used approach to produce PLGA NPs.
Solvents such as acetonitrile with PLGA dissolved is hydrodynamically focused by a non-
solvent (water or buffer) to achieve tunable and rapid mixing, leading to nanoprecipitation of
NPs. Sun et al. developed a microfluidic origami chip with different geometries to produce
monodispersed doxorubicin (Dox)-loaded PLGA NPs with tunable size (70–230 nm) in a
single nanoprecipitation step through the rapid mixing of PLGA–Dox with water (Fig. 3A)
(Sun et al., 2013). The chip was fabricated by bonding two poly(dimethylsiloxane) (PDMS)
layers after oxygen plasma that could be folded manually to achieve different geometries
such as an arc and double spiral. The design achieved a throughput of 1200 mg of NPs per
day at a maximum flow rate of 2.5 mL/h for 2% PLGA–Dox solution. Karnik et al. prepared
docetaxel (Dtxl)-loaded poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA–PEG)
NPs through rapid and tunable 2D hydrodynamic flow focusing (HFF) in microfluidic
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channels (Karnik et al., 2008). By varying the flow rates, polymer composition and polymer
concentration, the Dtxl-loaded PLGA–PEG NPs had a smaller size, a lower dispersity (Ð),
and a higher drug loading with a slower release than the ones synthesized using bulk
preparation methods. However, one of the challenges of using 2D HFF was that the NPs had
the tendency to aggregate, thus clogging the channel, when the PLGA block has a molecular
weight (Mw) higher than 45 kDa, resulting in an irreversible failure. Rhee et al. designed a 3D
HFF device composed of a monolithic single layer with three sequential inlets for vertical
focusing in combination with a cross junction for horizontal focusing (Fig. 3B) (Rhee et al.,
2011). NPs of different polymer concentrations and Mw that were otherwise difficult to
assemble by either 2D HFF or bulk preparation methods were successfully fabricated using
this 3D HFF method. Mathematical modeling along with simulation and confocal microscopy
led  to  the  prediction  of  optimal  ranges  for  the  reproducible  synthesis  of  PLGA  NPs,  so
realized the prevention of fouling and enhancing the robustness of operation. Valencia et al.
developed a modified 3D HFF for the on-chip combinatorial synthesis of targeted polymeric
NPs, thereby combining the 3D HFF and micromixing (Fig. 3C) (Valencia et al., 2013).
PLGA–PEG NPs of various size (25 to 200 nm), surface charge (–20 to +20 mV), target
ligand density (0 to ∼105 ligands/μm2), and with an anticancer-drug loaded (0 to 5%) were
synthesized on-chip in a rapid and reproducible manner. A library of 45 different
formulations was then screened in vitro and in vivo. Lim et al. developed a microfluidic
parallelization method using a multilayer 3D HFF to enable high-throughput NP synthesis
with tunable particle size (Fig. 3D) (Lim et al., 2014). The production rates can be increased
considerably by using eight 3D HFFs (84 mg/h) in parallel in comparison with a single 3D
HFF  (4.5  mg/h)  at  similar  flow  conditions.  Furthermore,  low Mw PLGA block (10 kDa)
yielded small NPs (~13 nm), while high Mw PLGA block (95 kDa) and high polymer
concentration produced large NPs (~150 nm), with both having uniform size distribution and
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minimum batch-to-batch variability. This is appealing as smaller NPs are able to penetrate in
vivo into solid tumors more effectively while acknowledging the fact that it is highly
challenging to fabricate drug-loaded polymeric NPs with controlled-release properties in that
size range via bulk synthesis routes.
Fig.  3 Designs of microfluidic devices for the synthesis of synthetic polymer nanoparticles.
(A) Microfluidic origami chip: (a) Schematics of a microfluidic origami chip for the synthesis
of monodisperse doxorubicin (Dox)-loaded poly(lactic-co-glycolic acid) (PLGA)
nanoparticles (NPs); (b) An arc geometry obtained by manually folding the origami chip; (c)
A double spiral geometry obtained from the same chip. Reprinted from (Sun et al., 2013),
Copyright (2013), with permission from Elsevier. (B) Schematics of a 3D hydrodynamic flow
focusing (HFF) device consisting of three sequential inlets for vertical focusing and a
separate inlet for side sheath flows. Reproduced with permission from (Rhee et al., 2011).
Copyright (2011) John Wiley & Sons Inc. (C) Microfluidic platform for the rapid synthesis of
PLGA-PEG NPs. Reprinted with permission from (Valencia et al., 2013). Copyright (2013)
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American Chemical Society. (D) 3D HFF microfluidic device for the parallel synthesis of
PLGA-PEG NPs in acetonitrile (ACN). Reprinted from (Lim et al., 2014), Copyright (2014),
with permission from Elsevier.
2.2.2 Natural polymer nanoparticles
Natural polymers have been widely exploited for pharmaceutical applications owing to
their marvellous properties. There are mainly two types of frequently used natural polymers
for nanoparticle preparation: chitosan and alginate.
Chitosan is a hydrophilic polysaccharide derived from the exoskeleton of insects,
crustaceans, and fungi. It has great potential in various applications due to its gel-forming
capability, high adsorption capacity, biocompatibility, non-toxicity, low-immunogenicity, and
biodegradability (Dash et al., 2011; Park et al., 2010). The reactive functional groups
(primary amine and hydroxyl groups) of chitosan allow specific chemical modifications to
form different derivatives for drug delivery applications (Prabaharan, 2015).  Microfluidics is
attractive for making chitosan nanoparticles. Although fast mixing in microfluidics remains a
challenge due to its laminar flow characteristics (Rhee et al., 2011), it has been demonstrated
computationally  (Kamat  et  al.,  2015)  and  experimentally  (Cetin  et  al.,  2014;  Chen  et  al.,
2014b; Majedi et al., 2014) that introducing active mixers can facilitate rapid mixing through
chaotic advection and diffusion. Cetin et al. designed a microfluidic device (Fig. 4A) with
micro-obstacle structures to enhance mixing thus enabling high throughput production (Cetin
et al., 2014). Majedi et al. made a T-shaped microfluidic device with a hydrodynamically
focused flow that had well-controlled mixing regime to synthesize monodispersed chitosan
NPs (Fig. 4B) (Majedi et al., 2014). The physical (e.g., size and zeta potential) and chemical
(e.g., biocompatibility) properties of the chitosan NPs can be tuned by controlling the mixing
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time and by using controlled pH-changes in water to drive the assembly of NPs, respectively.
Hydrophobic anticancer drugs, like paclitaxel, can be encapsulated at high efficiency (>95%),
and the drug’s potency can be preserved much better than conventional encapsulation
methods. These nanoparticles synthesized in microfluidic devices had lower release rate at
pH 7.4, which was desirable for long-term circulation stability owing to their compact
nanostructures,  and  higher  release  rate  at  pH 5.5  at  tumor  sites.  Additionally,  chitosan  NPs
have also been used as an adjuvant. For example, chitosan/cytosine-phosphodiester-guanine
oligodeoxynucleotide (CpG ODN) NPs prepared using a microfluidic method exhibited
enhanced cellular uptake and immunostimulatory response in comparison to the NPs
synthesized via the conventional bulk mixing method (Chen et al., 2014b).
Fig.  4 Microfluidic devices for the synthesis of chitosan nanoparticles. (A) Microfluidic
channel network with five inlet reservoirs. Copyright 2013 by ASME. Reproduced with
permission from (Cetin et al., 2014). (B) Schematic representation of a T-shaped microfluidic
device which is used to hydrodynamically flow focus high molecular weight chitosan
supplement (HMCS) using a sheath flow of water at basic pH (top). Transmission electron
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micrograph (TEM) images of nanoparticles prepared from HMCS with three different degree
of  substitution  (a–c).  Copyright  Wiley-VCH Verlag  GmbH & Co.  KGaA.  Reproduced  with
permission from (Majedi et al., 2014).
Alginate is a water-soluble linear anionic polysaccharide extracted from the brown
seaweeds. It has potentials for numerous pharmaceutical and biomedical applications due to
its attractive properties such as mucoadhesivity, biodegradability, and biocompatibility.
Alginate NPs can be formed by polyelectrolyte complexation in which calcium (Ca)-alginate
pre-gels interact with cationic polymers thus forming NPs through ionic interactions (Paques
et al., 2014). However, conventional non-homogeneous mixing methods result in micro
aggregates of broad size distribution that prevent their use in practical applications. To
minimize aggregation and narrow size distribution, Kim at al. fabricated alginate NPs using
the polyelectrolyte complexation between anionic Ca-alginate pre-gel and cationic poly-ʟ-
lysine (PLL) in a microfluidic mixing device (Fig. 5A) (Kim et al., 2015c). By changing the
flow  rates  of  the  Ca-alginate  pre-gel  and  PLL  solutions,  the  size  of  alginate  NPs  could  be
controlled (380 to 520 nm). Another method to form alginate NPs was through a microbubble
bursting process in a T-junction microfluidic device (Fig. 5B) (Elsayed et al., 2015). The
alginate NPs can be produced with different sizes (80 to 200 nm) depending on the viscosity
of the solution used to prepare the alginate microbubbles.
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Fig.  5 Microfluidic devices for the synthesis of alginate nanoparticles. (A) T-junction
microchannel for creating alginate microbubbles (i) and schematic of the alginate
microbubble bursting to form alginate nanoparticles as shown in the scanning electron
micrograph (SEM) image (scale bar: 1 µm). Reprinted from (Elsayed et al., 2015), Copyright
(2014), with permission from Elsevier. (B) Microfluidics-aided polyelectrolyte complexation.
The transmission electron micrograph (TEM) image shows alginate nanoparticles (scale bar:
1 µm). Reprinted from (Kim et al., 2015c), Copyright (2015), with permission from Elsevier.
2.2.3 Liposomes
Liposomes are spherical-like vesicles with an aqueous core entrapped by one or more
lipid bilayers. Since synthesized in the 1960s for the first time, liposomes have been
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intensively studied as hollow and flexible nanocarriers because of their superior
biocompatibility and biodegradability. In the past decades, bulk synthesis methods, such as
freeze-thaw cycling, film hydration, alcohol injection and detergent depletion, have been
developed (reviewed in (van Swaay and deMello, 2013)). However, these conventional
methods  usually  require  post-processing  steps,  such  as  sonication  or  extrusion,  to
homogenize the size as well as to narrow the size distribution, which may cause batch-to-
batch variability thus limit their commercial applications. Microfluidic technology has led to
a new way of redefining the “exquisite and dynamic control” of the preparation of liposomes.
A number of microfluidic methods became available, including pulsed jetting (Funakoshi et
al., 2007), droplet-based microfluidics (Kong et al., 2015; Ryan et al., 2012), microfluidic
hydrodynamic focusing (MHF) (Jahn et al., 2004) and vertical flow focusing (VFF) (Hood
and DeVoe, 2015). The pulsed jetting and droplet-based microfluidics are mainly designed
for producing micrometer-sized lipid vesicles, and the MHF and VFF methods are widely
used for making nanoscale liposomes. In the MHF method, the central stream of the lipids
solutions meets with the two side channels containing an aqueous buffer and then initiates the
self-assembly of the liposomes (Fig. 6) (Jahn et al., 2004). Because of the  fast mixing in the
MHF, liposomes with high reproducibility and controllable size were fabricated (Belliveau et
al., 2012; Hood et al., 2014; Jahn et al., 2004). Higher flow rate ratio of the volumetric flow
of  the  aqueous  buffer  to  that  of  the  lipids  solution  results  in  smaller  size  and  better
monodispersity (Jahn et al., 2013; Jahn et al., 2010; Mijajlovic et al., 2013; Phapal and
Sunthar, 2013). Furthermore, a VFF approach using a large microchannel aspect ratio
(channel depth to channel width), up to 100:1, was developed for producing liposomes at a
throughput of nearly 100 mg/h (Hood and DeVoe, 2015), which makes the microfluidic
technology promising for fabricating liposomes for practical applications.
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Fig.  6 Schematic of the synthesis of liposome in microchannel by using 2D (A) and 3D (B)
microfluidic hydrodynamic focusing (MHF) methods. Dissolution of alcohol into water leads
to a decreased solubility of the lipid materials. As a consequence, the lipid gradually
aggregates into bilayer planar disc and eventually close into liposomes. Reprinted with
permission from (Jahn et al., 2004). Copyright (2004) American Chemical Society.
Liposomes have been developed as nanocarriers by loading various functional cargoes
for pharmaceutical applications, including drugs (Hood et al., 2014; Kastner et al., 2015) and
genes  (Balbino  et  al.,  2013;  Belliveau  et  al.,  2012;  Chen  et  al.,  2012).  The  cargo  can  be
loaded into liposomes either by active or passive loading. Hood et al. prepared doxorubicin
(Dox)-loaded liposomes in an integrated microfluidic mixing device using a one-step
continuous-flow process which combined liposome synthesis and drug loading (Hood et al.,
2014). Briefly, liposomes were first formed in an MHF section and then flowed to a counter-
flow microdialysis element where buffer exchange occurred. The resulting pH shifting of the
solution enabled steep transmembrane ion gradients prior to remote drug-loading in the
incubation zone (active loading) (Fig. 7). This process produced ‘coffee bean’-like liposomes
having a diameter of 190 nm and Dox-encapsulation efficiency of 72%. Kastner et al. loaded
a hydrophobic drug, propofol, into liposomes by simply mixing the hydrophobic drug and
  
24
lipid solution before injected them to the microfluidic device (passive loading). This method
generated drug-loaded liposomes with a tunable size (50–450 nm) and higher loading
efficiency (41% mol) compared to liposomes formed using the conventional sonication
method (Kastner et al., 2015). Their drug release profile showed an initial release of 40% of
the encapsulated drug in 1 h, followed by a sustained release over another 16 h-period. Other
than chemotherapy drugs, genes can be loaded into liposomes for in vivo delivery. Chen et al.
encapsulated siRNA into cationic liposomes using a microfluidic device with a special
geometry design, i.e., staggered herring-bone micromixer (Chen et al., 2012). The resulting
liposomal  siRNA  had  a  diameter  of  60  to  90  nm  with  a  narrow  size  distribution  and  high
encapsulation efficiency (approximately 80%). The in vivo mice experiments using the
liposomal siRNA showed more than 90% target gene silencing efficiency. Additionally,
liposomes can be functionalized, e.g., with PEG and folate (Hood et al., 2013; Ran et al.,




Fig.  7 Schematic of the microfluidic synthesis of nanoscale liposome in-line with buffer
exchange via microdialysis and loading of doxorubicin drug. Vertical (A) and lateral (B)
views of the microfluidic device. Reproduced from (Hood et al., 2014) with permission from
The Royal Society of Chemistry.
2.2.4 Hybrid nanoparticles
Hybrid nanoparticles possess core–shell structures which can be classified as inorganic-
core organic-shell (Herranz-Blanco et al., 2015), organic-core inorganic-shell (Chen et al.,
2010) and organic-core organic-shell (Fang et al., 2010) NPs. Among them, organic-core
organic-shell, lipid–polymeric nanoparticles (LPNs) have received considerable attention for
pharmaceutical applications. LPNs are composed of a polymer core and a lipid shell
combining the advantages of both polymeric nanoparticles (e.g., sustained release and high
drug encapsulation efficiency) and lipid vesicles (e.g., excellent stability and
biocompatibility) (Zhang et al., 2008). Traditionally, the synthesis of LPNs involves two
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steps, that is, separately preparing polymeric nanoparticles and aqueous lipid
films/liposomes, followed by constructing core–shell nanoparticles through extrusion,
sonication, or electrostatic interaction (reviewed in (Hadinoto et al., 2013)). In contrast with
the bulk synthesis methods, microfluidic approaches combine nanoprecipitation of polymeric
materials and self-assembly of the lipid shell in a single step. So they offer advantages such
as minimal preparative steps, uniform size, better control over the hybrid particles’
physicochemical properties (e.g., size, zeta potential, and shell stiffness), adjustable
throughput and superior reproducibility (Table 1). For example, Valencia et al. synthesized
stable and homogenous LPNs having tunable size (35–180 nm) and zeta potential (–10 to +20
mV) (Fig. 8) (Valencia et al., 2010). More importantly, their shell rigidity was controlled to
regulate the cellular uptake. Sun et al. prepared LPNs having structures of PLGA–lipid and
PLGA–water–lipid (by altering the injection order of the PLGA and lipid–PEG organic
solutions in the microfluidic chips) which had Young’s modulus of 1.2 and 0.76 GPa,
respectively (Sun et al., 2015). They found that the more rigid NPs had a much higher
cellular uptake than the less rigid ones. To achieve the high-throughput synthesis of LPNs, a
microfluidic device was designed to operate at high Reynold numbers (up to 150) using
controlled microvortices. It can achieve a production rate of 3 g/h, which was 1000 times
higher than the diffusion mixing in a microfluidic flow-focusing pattern and 200 times faster
than convective mixing in a Tesla-type mixer (Kim et al., 2012).
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Fig.  8 Schematic of the synthesis of lipid–polymeric nanoparticles composed of poly(lactic-
co-glycolic acid) (PLGA)-core lipid-shell (in blue arrow) and quantum dots-core lipid-shell
(in red arrow) hybrid nanoparticles in the microchannels and the corresponding electron
microscopy images. Adapted with permission from (Valencia et al., 2010). Copyright (2010)
American Chemical Society.
Table  1 Representative examples of lipid-polymeric hybrid nanoparticles fabricated using












180–280 n/a Low (Hong et al., 2010)




103–106 n/a Low (Zhang et al., 2015)
PLGA Lecithin, DSPE–PEG 30–170 n/a High (Kim et al., 2012)
PLGA EPC, DSPE–PEG 80 –40 High (Fang et al., 2012)
PLGA DPPC, cholesterol,
DSPE–PEG
40 0 Low (Sun et al., 2015)
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†High throughput: ≥1 g/h; low throughput: < 1 g/h. Abbreviation: PLGA, poly(lactic-co-glycolic acid); DSPE-
PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol); DPPC, dipalmitoyl-
sn-glycero-3-phosphocholine; NIPA, N-isopropylacrylamide; DCP, dihexadecyl phosphate; EPC, L-α-
phosphatidylcholine (egg PC); n/a, not available.
LPNs show promising prospect in the delivery of both hydrophilic and hydrophobic
drugs such as doxorubicin (Wong et al., 2006; Zhang et al., 2015) and docetaxel (Liu et al.,
2010), respectively. Drugs can be easily loaded by mixing with the polymer or the lipids in
the microfluidic device. Zhang et al. encapsulated doxorubicin and combretastatin A4 (CA4)
into PLGA-based LPNs for cancer treatment, and demonstrated the effectiveness of this drug
carrier in inducing significant cell apoptosis and tumor weight loss. Moreover, they found
that PLGA nanoparticles covered with lipid-monolayer-shells, rather than lipid-bilayer-shells,
demonstrated better anti-tumor efficacy (Zhang et al., 2015). Mieszawska et al. co-loaded
doxorubicin and sorafenib into PLGA-based LPNs using a microfluidic approach with
loading efficiencies of 25.6% and 66%, respectively (Mieszawska et al., 2013). The resultant
drug-loaded LPNs had a diameter of approximately 85 nm with low polydispersity (~0.1). In
vitro drug release profile showed a significant sustained release of both doxorubicin and
sorafenib within a period of 21 days. In vitro cytotoxicity study demonstrated that this dual
drug-loaded LPNs led to 72% inhibition against human colon cancer cell line (LS174T), and
in vivo images demonstrated a high accumulation of the LPNs at the tumor site. In addition to
loading drugs, nanoparticles such as quantum dots have been loaded into LPNs for imaging
(Fig. 8) (Valencia et al., 2010), demonstrating the versatility of hybrid nanoparticles in
encapsulating various types of cargoes.
3. Droplet-based 3D microgels for drug screening
A plethora of drug delivery carriers has been rationally designed and developed as
described above, which has the potential to enable the use of new drugs as well as to improve
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the performance of existing drugs. Their physicochemical properties affect their interactions
and behavior within the biological systems (toxicity and efficacy), thus requiring thorough
and systematic studies in vitro and in vivo before their clinical applications. Specifically, the
studies include the stability of the carriers within the body, their binding (localization) and
internalization at the cellular level, their fate inside the body and their toxicological effects,
and their efficacy compared to free drugs (Stirland et al., 2013). Animal models have been
used as the gold standard for validating drugs and drug delivery carriers in preclinical testing.
However, animal studies are time-consuming, expensive, low-throughput and raising ethical
concerns, which limit the pace of clinical translation of new drugs and drug delivery carriers.
In contrast, 2D monolayer cell culture models have been commonly used as the in vitro
models,  thereby  growing  cells  (either  freshly  isolated  from  human/animal  tissues  or  from
immortalized cell lines) on top of a flat substrate. However, they lack the complex 3D in vivo
microenvironment wherein cells and extracellular matrix exist in well-organized architecture,
as well as other issues such as scalability, batch-to-batch variability, and poor predictability.
To address these problems, microfluidic technologies offer alternative strategies to develop
robust 3D in vitro models that better recapitulate what naturally occurs in vivo.
3.1 Microgels for cell encapsulation and 3D cell culture
Microgels have been used to develop 3D in vitro cell cultures that mimic specific in
vivo cellular microenvironment by encapsulating living cells and subsequently culturing cells
within the gel matrix (attachment, spreading, growth, and proliferation). Various cells have
been encapsulated within microgels, such as MCF-7 breast cancer cells (Yu et al., 2015),
mesenchymal stem cells (Utech et al., 2015), human umbilical vein endothelial cells (Jung et
al., 2014), human epithelial carcinoma cells (Miyama et al., 2013), adenoid cystic carcinoma
cells (Shi et al., 2013), and Madin Darby canine kidney cells (Eydelnant et al., 2014). 3D cell
cultures in microgels offer several advantages, including tunable shear forces imposed on
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cells, easy visualization (e.g., by conjugating fluorescent agent to the microgel’s material
(Utech et al., 2015)), easy control over the transport of oxygen, nutrients, growth factors and
waste (McGuigan and Sefton, 2007) as well as the mechanical and chemical stability in
aqueous media such as buffer or cell culture media.
Microgels can be made of synthetic and natural polymers as previously described
(Section 2.1.3). Synthetic polymer-based microgels did not gain popularity in cell culture
applications due to the harsh conditions involved in the process of microgel preparation, such
as strong shear forces, ultraviolet irradiation, and large temperature gradients, which cause
severe cell damage or even mortality (Velasco et al., 2012). In contrast, natural polymer-
based microgels,  such as alginate (Eydelnant et  al.,  2014; Miyama et  al.,  2013; Utech et  al.,
2015; Yu et al., 2015), agarose (Eydelnant et al., 2014; Shi et al., 2013) and chitosan (Jung et
al., 2014), are widely used for cell encapsulation because of their biocompatibility and mild
conditions required to achieve gelation, thus preserving cell viability. Cross-linking methods
for gelation affect significantly the network structures of the formed microgels, so the ability
to control cross-linking process allows the formation of homogeneous network structure with
precise internal structure and tunable stiffness (Jung et al., 2014; Utech et al., 2015), enabling
the stable entrapment of cells in a controlled microenvironment. Utech et al.  prepared
monodisperse, structurally homogeneous alginate microgels in the size range of 10–50 µm by
the on-demand release of calcium ions from a water-soluble calcium–EDTA complex to
initiate the ionic cross-linking (Utech et al., 2015). The ability to produce microgels with
tunable size and high degree of uniformity is of key importance for cell encapsulation and
cell culture within gel matrices, since cell–cell distances and structural arrangement have a
significant influence on cellular properties and functions. Additionally, the degradability of
microgels is essential for enhancing cell viability during long-term cell culture. Moreover, gel
matrices can be fabricated to possess various hierarchical structures and any desired shape to
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support cell culture, such as yarn-ball-shaped (Miyama et al., 2013), core–shell (Yu et al.,
2015) or tubular (Jung et al., 2014). For example, Miyama et al. synthesized yarn-ball-shaped
microgels which had an average outer diameter of 200 µm with fibers of 10–30 µm. They
had a large void volume and a high surface-to-volume ratio, which provided sufficient
permeability to promote effective delivery of oxygen, nutrients, and metabolic products to the
encapsulated cells (Miyama et al., 2013). Yu et al. prepared alginate microgels having a
structure of alginate-core/alginate-shell in which the core acted as 3D culturing unit while the
shell  prevented   cells  from  diffusing  out  of  the  microgels  and  subsequently  proliferate  and
form monolayer in the culture-flask as occurred to the core-only microgels (Yu et al., 2015).
3.2 3D cell culture for tumor-on-a-chip
Numerous types of nanoparticles (NPs) have been synthesized for pharmaceutical
applications as previously described (Section 2.2). The delivery of these NPs to tumor sites is
very complex. NPs can undergo multiple transport processes, such as blood flow-driven
movement, NP–endothelium interactions and extravasation, and confront pathophysiological
barriers, such as elevated interstitial pressure (Heldin et al., 2004). Recently, tumor-on-a-chip
has emerged as a new system to evaluate the delivery of NPs, providing physiological
relevance, organ-level function as well as enhanced throughput and reduced cost. A Tumor-
on-a-chip model normally consists of tumor cells or spheroids representing tumor tissues and
microchannels mimicking the blood flow.
To date, several tumor-on-a-chip platforms, including breast, lung, brain and liver
tumor on-a-chip, have been established for various purposes (Table 2). Albanese et al.
immobilized a multicellular melanoma tumor spheroid in a microfluidic device to evaluate
the accumulation of gold NPs at tumors under physiological interstitial flows  (Fig. 9)
(Albanese et al., 2013). PEG-functionalized gold NPs having a smaller size (40 and 70 nm)
accumulated at the tumor spheroid to a greater extent than the larger NPs (110 and 150 nm).
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Functionalizing the NPs (40 nm) with a targeting molecule (i.e., iron-transporting transferrin
protein (Tf)) further improved their accumulation and retention. Also, higher flow rates
resulted in better accumulation but predominantly in the ECM around the spheroid. In vivo
xenograft tumor model in mice further validated these results except the enhanced receptor
targeting effect (Albanese et al., 2013). Prabhakarpandian et al. designed and fabricated a
tumor-on-a-chip with a complex tumor-vascular network (Fig. 10A) (Prabhakarpandian et al.,
2015), mimicking the morphology, fluidics and leaky vasculature of tumor microenvironment
in vivo. Endothelial cells and 3D cervical tumor spheroids separated by the leaking gaps were
co-cultured in the network (Fig. 10B) (Prabhakarpandian et al., 2015). The chip was used to
predict in vivo delivery efficacy of two commercial nano polymer gene delivery vehicles (i.e.,
PPC and Express-In).  The behavior of the delivery carriers (labeled with Rhodamine) under
the  flow  of  serum  proteins  were  observed  in  the  synthetic  tumor  network  (Fig.  10C).  PPC
showed uniform distribution and minimal aggregation across the vascular and the tumor
regions, whereas Express-In showed the opposite. Furthermore, the GFP expression using
PPC and Express-In polymers injected into the tumor network were quantified using two
different methods (direct and vascular) (Fig. 10D). Vascular injection showed higher
efficiency for PPC while direct tumor injection showed similar results for both the polymers,
although Express-In based-GFP expression signal was slightly higher. The results obtained
from the synthetic tumor network were consistent with the in vivo delivery performance
(Prabhakarpandian et al., 2015). Kwapiszewska et al. developed the SpheroChip, consisting
of disposable microfluidic chips for cell culture and a positioning plate, to culture human cell
lines (i.e., HT-29 colon cancer cells and Hep-G2 hepatocytes). After the injection of
anticancer drug 5-fluorouracil (5-FU), the dynamic changes on the metabolic activity of the
cells in response to the drug could be monitored and analyzed continuously (Kwapiszewska
et al., 2014). Ruppen et al. observed a higher chemoresistance in primary co-culture
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spheroids (i.e., primary lung cancer epithelial cells and primary pericytes) than in primary
monoculture spheroids in a Lung-on-a-Chip model, which could serve as a more
chemosensitive tumor model (Ruppen et al., 2015). More deep understanding about tumors is
expected to be unveiled as the tumor-on-a-chip technique develops, which will contribute
enormously to drug and nanocarrier designing, screening, and evaluation.
Fig.  9 Tumor-on-a-chip platform to study tissue transport behaviour of engineered gold
nanoparticles (NPs). (A) Schematic illustration of the tumor-on-a-chip. (B) Optical view of
the tumor-on-a-chip (scale bar, 1000 µm) (left) contained a spheroid (stained with anti-
Laminin-fluorescein isothiocyanate) which was surrounded by a non-uniform layer of
extracellular matrix (ECM) that acted as a physical barrier between the cells and the medium
(scale bar, 100 µm) (right). (C, D) Localization (C) and kinetics (D) of tissue accumulation of
Tf-functionalized NPs. The NPs predominately accumulated in the ECM surrounding the
tumor spheroid (sphr) and that a targeting ligand (Tf) provided an “anchoring effect”,
reducing efflux during flushing/washing. (E) Representative image of tumor fluorescence
from in vivo mouse model injected with the Tf-functionalized NPs, showing that the result
was largely in an agreement with those obtained using microfluidic in vitro model.
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Reproduced with permission from (Albanese et al., 2013). Copyright (2013) Nature
Publishing Group.
Fig. 10 Synthetic  tumor  network  on  chip.  (A)  Conceptual  design  of  the  synthetic  tumor
network on-chip consisting of vascular channels (for culturing endothelial cells) and tissue
compartment (for culturing tumor) cells separated by walled barrier with the 2 µm leaking
gap to mimic “leaky vessel” in tumor microvasculature in vivo.  (B) Co-culture of 3D HeLa
cells (cultured on microfabricated scaffolds) and endothelial cells (cultured in the vascular
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lumen) separated by the walled barrier (scale bar: 250 mm). (C) Difference in the behavior of
two commercial nanopolymer based gene delivery systems (labelled in Rhodamine
fluorescent tag) in the synthetic tumor network (scale bars: 250 mm). (D) Quantification of
green fluorescent protein (GFP) intensity expressed in PPC and Express-In following
vascular and direct injection. Reprinted from (Prabhakarpandian et al., 2015), Copyright
(2015), with permission from Elsevier.
Table 2 Representative examples of tumor-on-a-chip models and their applications.
Cancer model Object Applications Ref.
Skin melanoma – Association between
cancer and immune system
(Businaro et al., 2013)




(Kwapiszewska et al., 2014)






(Yang et al., 2015)




(Aref et al., 2013)
Cisplatin Chemosensitivity
evaluation
(Ruppen et al., 2015)
Brain glioma Anticancer drugs (e.g.,
vincristine and bleomycin)
Therapeutic efficacy (Liu et al., 2015b)
Liver cancer – Tumor immune
surveillance
(Christakou et al., 2015)




3.3. 3D cell culture for organs-on-a-chip
So far, we have witnessed too many examples of new drugs that failed at late stages of
their clinical trials, which is a heavy blow to the related pharmaceutical companies as well as
public’s confidence in fighting against devastating diseases such as cancer. The development
of new drugs or new formulations has been extremely costly and time-consuming. The reason
in relating to this is primarily due to the poor prediction capability of preclinical studies using
existing preclinical models. Therefore, the importance of creating new models to generate
reliable preclinical data of drug safety and efficacy has repeatedly been emphasized by the
drug discovery community. Similar to tumor-on-a-chip (Section 3.2), organs can also be
reconstructed in microfluidic devices to generate organs-on-a-chip systems. By applying 3D
tissue culture or organoids in integrated microfluidic networks, such models can replicate the
key functions of organs inside our body. Furthermore, the precise control over microfluidic
flows offers advantages such as mimicking blood circulation, controlling over chemical and
biomolecular gradients, and providing continuous medium exchange. Therefore, organs-on-a-
chip models (Table 3) have great potential in mimcking the behavior and efficacy of
drugs/nanoparticles more accurately than conventional 2D cell cultures, much faster and less
expensive than in vivo animal models.
Table 3 Recently reported single and multiple organ-on-chip systems and their applications.
Organ(s) Object Applications Ref.
Lung Nanoparticles and
interleukin-2
Inflammation, toxicity (Huh et al., 2012; Huh et
al., 2010)





(Bruce et al., 2015)
Blood vessels – Vascular function (Kim  et al., 2015b;
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Wang et al., 2014b)
Kidney Cisplatin Toxicity (Jang et al., 2013)
Brain – Brain function, Alzheimer's
disease
(Berdichevsky et al.,
2010; Park et al., 2015)








(Imura et al., 2012)
Liver, bone
marrow, tumor
Anticancer drug (e.g., 5-
fluorouracil)













Anticancer activity (Ma et al., 2012)
Liver, skin Troglitazone Toxicity (Wagner et al., 2013)
Lung-on-a-chip was the first trial of the concept of organ-on-a-chip. A layer of human
alveolar epithelial cells and a layer of human pulmonary microvascular endothelial cells were
co-cultured on the opposite sides of a thin porous elastomeric membrane to simulate the
alveolar–capillary interface (Huh et al., 2010). This microfluidic design enabled the
application of differential media, shear stress, and a mechanical stretch–shrink movement
over the cells simultaneously to mimic the physiological breathing motions (Figs. 11A, B).
Exposing the epithelial side to 20 nm-diameter NPs (Fig. 11C) resulted in the toxic and
inflammatory response as indicated by translocation of the NPs across the alveolar–capillary
interface as well as increased reactive oxygen species (ROS) production and intercellular
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adhesion molecule-1 (ICAM-1) expression. More importantly, the NP translocation was
significantly augmented by applying the cyclic mechanical lateral stretching, an effect that
could not be obtained using conventional Transwell cultures (Fig. 11D). A whole-mouse-lung
ventilation-perfusion model was then used to determine the physiological relevance of this
observation. After the intra-tracheal injection into the breathing mouse lung, the 20-nm NPs
reached the surface of alveolar epithelium and the underlying interstitial space and
microvasculature (Fig. 11E), and the NP transport from the alveoli into the microvasculature
was significantly increased in the presence of cyclic breathing in vivo (Fig.  11F),  similar to
those observed in the lung mimic device in vitro (Fig. 11D). This lung-on-a-chip model was
also utilized to investigate the toxicity of an anticancer drug interleukin‑2 (IL‑2) aiming to
discover new drug candidates (Huh et al., 2012). In another study, the brain was grafted onto
a microchip, and axons formed between the cortex and the hippocampus. Moreover, the
selective pharmacological manipulation of activities in the constituent slices was
demonstrated, which could help us to understand the development, plasticity, and pathologies
of neural systems. Other organs such as bone marrow and kidney have also been successfully
“transplanted” into microfluidic systems to establish microengineered models for various
applications (Table 3). These systems could be of great support in obtaining preclinical data
such as toxicity and maximum tolerated doses.
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Fig. 11 Lung-on-a-chip. (A) Schematic of on-chip cell culture model providing
microenvironment mechanical stimuli for reconstituting organ-level function of lung. (B)
Photograph of the actual lung-on-a-chip device. (C) Transport of nanoparticles (NPs) from
the alveolar chamber to the vascular channel of the lung-on-a-chip, simulating transport
across the alveolar-capillary interface of the lung. (D) Toxicological test of 20-nm NPs using
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the lung-on-a-chip: 10% mechanical strain was applied to simulate breathing motions
compared with static controls in this device or in a Transwell culture system. (E–F)
Validation  of  the  toxicity  of  the  20-nm  NPs  using  the  whole  mouse  lung:  fluorescence
micrographs  of  a  histological  section  of  the  lung  showing  the  NPs  locations  (E)  and  the
number of NPs absorbed into the blood perfusate over time with and without physiological
cyclic breathing through application of mechanical ventilation in the lung (F). PC, pulmonary
capillary; AS, alveolar space; blue, epithelial nucleus; scale bar, 20 µm. Reprinted from (Huh
et al., 2010) with permission from The American Association for the Advancement of
Science.
Apart from single organ models, multiple organs on a chip (organs-on-a-chip) have also
been established by biologically connecting different tissues or organs to study their
collective effects (Table 3). For example, chambers containing intestine, liver, and breast
cancer cells were connected in series to investigate the absorption, metabolism, and activity
of  an  anticancer  drug  after  oral  delivery  (Fig.  12)  (Imura  et  al.,  2012).  In  another  study,  a
colon tumor, liver, and bone marrow were combined to explore the in vivo metabolism and
cytotoxicity of the anticancer drug 5-fluorouracil (5-FU) (Sung et al., 2010). Similarly, Ma et
al. reconstituted liver and brain tumor on a microchip, and found that the activation of
ifosfamide by the liver led to enhanced brain tumor cytotoxicity (Ma et al., 2012). These
findings may provide important primary pharmacokinetical and pharmacodynamical (PK/PD)
data for discovering novel drugs. Although we have not yet seen a successful precedent of
any organ-on-chip model for the commercial development of novel drugs, this technology
has gradually been incorporated into various fundamental research and hold great promise in
accelerating the development of novel drugs and drug delivery carriers.
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Fig. 12 Organs-on-a-chip. Cross-sectional illustration (drawn not to scale) of the multi-organ
model representing stomach digestion, intestine absorption and liver metabolism before an
anticancer drug reaching tumor site after oral delivery. Reprinted from (Imura et al., 2012)
with permission from The Japan Society for Analytical Chemistry.
4. Perspective
Convergence of microfluidics and material fabrication provides an attractive strategy
for making micro- and nanomaterials with controlled properties for pharmaceutical
applications. The flexibility of tuning the properties of these materials precisely such as size,
surface charge, surface morphology, hierarchical structure, etc., and the possibility of
producing them in a reproducible and scalable manner have led researchers to develop a
plethora of various micro- and nanomaterials exhibiting unique properties and promising
functions, and the research focus has moved gradually from the initial efforts in developing
different microfluidic devices and strategies in precisely controlling micro- and nanosystems’
physical properties, such as size, monodispersity, shape, surface charge, and texture, to recent
attempts in fabricating micro- and nanosystems with more complex structures, such as core–
shell, Janus and nano-in-micro, carrying multi-components, such as two or more drugs,
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quantum dots and MRI agents. These engineered micro- and nanosystems often can achieve
multiple functions, including triggered release by pH, temperature, light, and even external
fields such as ultrasound, heating, etc., targeted delivery by integrating targeting ligands or
external magnetic force, and real-time therapeutics and imaging for theranostics. Although
the advance in this field is fast, the translation of these micro- and nanosystems has been slow
due to two main obstacles. One is that most of the appealing properties such as complex
structures and multifunctions will lose their advantages that have been demonstrated in in
vitro models once they are introduced to the real in vivo systems and ultimately in human.
Specifically, more complexities and functions mean more convoluted behavior and effects in
vivo, thus making it more difficult in understanding the interactions between these micro- and
nanosystems and the biological systems at all levels from cell through to tissue and organs.
On the other hand, the lack of quick, cheap and reliable models represents another obstacle to
understand these complicated interactions.
          The transition from 2D to 3D models is a critical step towards more physiologically
relevant tissue models. However, traditional 3D culture techniques suffer from several
limitations. For example, they did not capture the multicellular complexity of tissues, were
lack of vasculature, cannot provide control over gradients, and cannot offer medium
exchange in a continuous manner. Microfluidics can overcome all of these limitations by co-
culturing cells in a spatially controlled manner, generating and controlling gradients, and
integrating continuous perfusion and flow. Therefore, significant research interest has been
attracted in developing various microfluidic 3D cell culture models, tumor-on-a-chip, organs-
on-a-chip or even human body-on-a-chip. After a decade of intensive research, considerable
progress has been achieved in this field, and the bottle neck for developing microfluidic
models has shifted from design of different microfluidic model systems to their validation
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and implementation. As the initial intent was to develop models that better mimic human
biology, animal models, despite their wide use, are thus not suitable for validation. Ideally,
the microfluidic models can be validated using available clinical data. However, there are not
much data available publically. Alternatively, relevant biological functions or biological
biomarkers can be used for validation. In this respect, the challenge would be using analytical
tools that are sensitive enough to be able to detect the biomarkers over a range of
concentrations from a small amount of samples. Additionally, to better mimic human
biology, primary cells from human are necessary for forming 3D cultures. However, there are
several  challenges  for  using  primary  cells  such  as  hard  to  culture,  short  life  span  in  vitro,
batch-to-batch variation. Stem cell techniques, especially induced pluripotent stem cells
(iPSc)  and  the  progress  in  controlling  differentiation  of  the  stem  cells  could  provide  a
solution. Integration of stem cells or organoids with microfluidic models could revolutionise
current development of microfluidic-based models. Although it is still at a very early stage of
their development, the advent of organs-on-a-chip platforms will surely provide valuable
inputs in exploring the complex interactions, thus deepening our understanding of the
ultimate requirement of the design of micro- and nanosystems for real pharmaceutical
applications.
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Highlights
· Multiphase microfluidics for the synthesis of micro-/nanostructures is presented.
· Development of carriers with multiple functionalities and components is discussed.
· Utilization of microfluidics towards developing biomimetic chips is highlighted.
· Special emphasis is on tumor-on-a-chip and organs-on-a-chip for carriers evaluation.
